Notably, the number of patent applications in the pharmaceutical industry was 68,003 in Q2 2023, versus 57,383 in the prior quarter. Filings were down 7% year-on-year and decrease 18% quarter-on-quarter. This compares to a 7% year-on-year decrease in patent grants and 18% rise in quarter-on-quarter.
Most patenting activity has been in the Mobiles, Hand-Helds, PDAs, Smartphones sector, where the number of patents filed Q1 2023 was 529, a rise of 8% versus the previous quarter. The second-largest patent count was in Printed Circuit Manufacturing (202, down 7%) and then Semiconductors in third (180, down 3%).
The top five companies accounted for 3% of patenting activity
Analysis of patenting activity by companies shows that the largest number of patents filed over the last quarter was by Chinese Academy of Sciences with 639, followed by F. Hoffmann-La Roche with 483 and Zhejiang University with 358.
Patenting activity was driven by China with a 37% share of total patent filings
The largest share of patent filings in the pharmaceutical industry in Q2 2023 was in China with 37%, followed by the US (13%) and Japan (7%). The share represented by China was 12% higher than the 25% share it accounted for in Q1 2023.
For further understanding of GlobalData’s Healthcare Expenditure and Pharmaceutical Sale Analysis, buy the report here.
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Patent Analytics tracks patent filings and grants from official offices around the world. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.